Article Text

PDF

A comprehensive coping strategy programme reduced nausea and fatigue after autologous bone marrow transplantation for breast cancer
  1. Karl-Heinz Schulz, MD, PhD
  1. University Hospital Eppendorf Hamburg, Germany

    Statistics from Altmetric.com

    
 
 QUESTION: In women having autologous bone marrow transplantation (ABMT) for breast cancer, does a comprehensive coping strategy programme (CCSP) reduce pain, fatigue, psychological distress, and nausea?

    Design

    Randomised (unclear allocation concealment*), {blinded (clinicians, outcome assessors, and statisticians)}*, controlled trial with 7 days of follow up after ABMT.

    Setting

    A comprehensive cancer centre in the eastern US.

    Patients

    110 women who were ≥18 years of age (53% were 41–50 y of age); had stage II, III, or IV breast cancer; and were scheduled for ABMT. Follow up was 100%.

    Intervention

    Women were allocated to CCSP (n=52) or no CCSP (n=58). CCSP consisted of preparatory information to increase control; cognitive restructuring, including positive coping statements and avoidance of catastrophising; and relaxation with guided imagery. A clinical social worker taught the CCSP intervention ≥2 weeks before hospital admission for chemotherapy and ABMT. The CCSP group received handouts on methods for reducing pain and psychological distress and increasing control, styles of distorted thinking to avoid, 15 positive coping self statements to use, and methods of relaxation therapy using an audiotape.

    Main outcome measures

    Pain (Gaston-Johansson Painometer); severity of nausea (100 mm visual analogue scale [VAS]); fatigue (100 mm VAS); and psychological distress (anxiety [State-Trait Anxiety Inventory] and depression [Beck Depression Inventory]).

    Main results

    The table shows the unadjusted results. At 7 days, nausea scores were lower in the CCSP group than in the control group (p<0.05). The CCSP group showed less combined nausea and fatigue than the control group after controlling for demographic variables. Groups did not differ at 7 days for pain or psychological distress.

    Comprehensive coping strategy programme (CCSP) v no CCSP with autologous bone marrow transplantation for breast cancer‡

    Conclusion

    In women with breast cancer who had autologous bone marrow transplantation, a comprehensive coping strategy programme reduced nausea and fatigue at 7 days.

    Commentary

    Psycho-oncology is a subdiscipline of oncology that focuses on the psychosocial effects of cancer on patients and their families, explores mediating effects of behavioural variables on cancer risk and disease symptoms, and evaluates the effectiveness of psychological interventions on the course of the disease.1 The studies by Gaston-Johansson et al and Fukui et al belong to the latter category of intervention studies that aim to reduce psychological distress in patients with breast cancer.

    Psychological intervention studies for patients with cancer, and especially for women with breast cancer, have been done since the late 1970s. This research culminated in the late 1980s and early 1990s in studies showing not only an improvement in psychological distress but also an increase in survival time2 and a reduction in recurrence.3 The publication of these papers led to a vast array of studies trying to replicate those findings, some of which also examined variables that might moderate the reported effects on disease course by using immunological and endocrine mechanisms.4 Those studies are a result of the confluence of psycho-oncological and psychoneuroimmunological expertise, and they set the standard against which later studies should be judged.

    The studies cited above focused mainly on long term outcomes, including survival and recurrence, whereas the studies by Fukui et al and Gaston-Johansson et al investigate short term effects on measures of psychological distress only. Although the results of both studies support previous findings, the short term effects are smaller than those reported earlier.5 This may be due to several methodological aspects. The patients in both studies represent a highly selected sample with minor affective disturbances as measured by baseline scores of depression and anxiety. Thus, further improvements may be hard to achieve with these outcome measures. In such studies it may be more appropriate to include measures of quality of life (QoL). Both studies claim that the intervention enhanced the QoL of the patients but neither study measured this construct directly. Numerous scales are available for an estimation of QoL, especially scales for patients with cancer.6 Furthermore, Gaston-Johansson et al used the Beck Depression Inventory, among other scales, which is an instrument designed for measuring depression in psychiatric patients. Therefore, a floor effect exists and little variance could be expected for this measure. The use of breast cancer specific measures is advised for future research.

    Both studies used multimodal intervention programmes, arguing that the diagnosis and treatment of cancer cause multidimensional psychosocial problems that are best addressed by multimodal programmes. Another review suggests that strictly focused approaches should be tested to determine the most effective one.5 This strategy could lead to interventions that are briefer and more economical and that help to identify the mechanisms responsible for the therapeutic effect. When applying such multimodal interventions, helpful and ineffective components are hard to differentiate from one another. Furthermore, the independent use of the programme's components and unspecific mutual support outside the sessions have not been assessed in the current studies.

    In summary, these studies provide further evidence that psychosocial interventions result in statistically significant improvements in mood or coping in patients with cancer. When discussing the generalisability of findings from intervention studies in psycho-oncology, however, the clinical relevance of results is a crucial point. Although some effects may be statistically significant, clinically relevant improvements may not be given. Thus, defining the clinically relevant endpoints in these trials is important. This can be achieved by using long term follow up assessments of survival time or disease free intervals. On the other hand, when using interventions that focus on psychosocial outcomes, measures should be chosen that are specific and responsive.

    References

    View Abstract

    Footnotes

    • Source of funding: US Department of Defense.

    • For correspondence: Dr F Gaston-Johansson, International and Extramural Programs, Johns Hopkins University School of Nursing, 525 North Wolfe Street, Baltimore, MD 21205-2110, USA. Fax +1 410 502 5481.

    • *See glossary.

    • †Information provided by author.

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.